For patients with metastatic clear cell renal cell carcinoma who did not benefit from checkpoint and tyrosine kinase inhibitors, limited alternative treatment options are available. ALLO-316 is a novel chimeric antigen receptor (CAR) T-cell therapy designed to recognize and kill cells expressing CD70, which is elevated in clear cell renal cell carcinoma. The TRAVERSE study, conducted by Samer Ali Srour, MBChB, MS, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues from other institutions, is a first-in-human trial evaluating ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma and is being presented at the 2025 ASCO Annual Meeting (Abstract 4508).
A total of 44 patients underwent lymphodepletion, and 39 received one infusion of ALLO-316. Dose-limiting toxicities were reported in 2 patients, 42 patients experienced treatment-emergent adverse events, and 25 patients developed cytokine-release syndrome. No case of graft-vs-host disease was observed. There was a 33% confirmed objective response rate for patients with CD70 in at least 50% of the tumor. The trial is ongoing. Researchers previously presented on the objective response rates and disease control rates.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
